161 related articles for article (PubMed ID: 30377659)
21. Assessing the Potential Cost-Effectiveness of Microneedle Patches in Childhood Measles Vaccination Programs: The Case for Further Research and Development.
Adhikari BB; Goodson JL; Chu SY; Rota PA; Meltzer MI
Drugs R D; 2016 Dec; 16(4):327-338. PubMed ID: 27696306
[TBL] [Abstract][Full Text] [Related]
22. Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens.
Kommareddy S; Baudner BC; Oh S; Kwon SY; Singh M; O'Hagan DT
J Pharm Sci; 2012 Mar; 101(3):1021-7. PubMed ID: 22190403
[TBL] [Abstract][Full Text] [Related]
23. Progress in hepatitis B prevention through universal infant vaccination--China, 1997-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 May; 56(18):441-5. PubMed ID: 17495790
[TBL] [Abstract][Full Text] [Related]
24. Novel Whole-Cell Inactivated
Gala RP; Zaman RU; D'Souza MJ; Zughaier SM
Vaccines (Basel); 2018 Sep; 6(3):. PubMed ID: 30181504
[No Abstract] [Full Text] [Related]
25. Undervaccination with hepatitis B vaccine: missed opportunities or choice?
Jiles RB; Daniels D; Yusuf HR; McCauley MM; Chu SY
Am J Prev Med; 2001 May; 20(4 Suppl):75-83. PubMed ID: 11331136
[TBL] [Abstract][Full Text] [Related]
26. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination.
Pichichero ME; Blatter MM; Reisinger KS; Harrison CJ; Johnson CE; Steinhoff MC; Senders SD; Rothstein EP; Willems P; Howe BJ
Pediatr Infect Dis J; 2002 Sep; 21(9):854-9. PubMed ID: 12352809
[TBL] [Abstract][Full Text] [Related]
27. Parameter optimization toward optimal microneedle-based dermal vaccination.
van der Maaden K; Varypataki EM; Yu H; Romeijn S; Jiskoot W; Bouwstra J
Eur J Pharm Sci; 2014 Nov; 64():18-25. PubMed ID: 25151530
[TBL] [Abstract][Full Text] [Related]
28. Dissolving Microneedle Patches for Dermal Vaccination.
Leone M; Mönkäre J; Bouwstra JA; Kersten G
Pharm Res; 2017 Nov; 34(11):2223-2240. PubMed ID: 28718050
[TBL] [Abstract][Full Text] [Related]
29. [Epidemiological characteristics of children aged 1-4 years without timely birth dose of hepatitis B vaccine vaccination in China, 2014].
Wang FZ; Zhang GM; Shen LP; Liu JH; Zheng H; Wang F; Miao N; Sun XJ; Liang XF; Cui FQ
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jan; 38(1):32-36. PubMed ID: 28100373
[No Abstract] [Full Text] [Related]
30. Microneedle Patches as Drug and Vaccine Delivery Platform.
Li J; Zeng M; Shan H; Tong C
Curr Med Chem; 2017; 24(22):2413-2422. PubMed ID: 28552053
[TBL] [Abstract][Full Text] [Related]
31. [Anti-HBs persistence following revaccination with three doses of hepatitis B vaccine among low-responsive adults after primary vaccination: a 4-year follow-up study].
Lyu JJ; Yin XW; Yan BY; Liu JY; Feng Y; Wu WL; Chen SY; Zhou LB; Liang XF; Cui FQ; Wang FZ; Zhang L; Xu AQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Jun; 50(6):491-6. PubMed ID: 27256727
[TBL] [Abstract][Full Text] [Related]
32. [Anti-HBs persistence following primary vaccination with three doses of hepatitis B vaccine among normal and high-responder adults: a 3-year follow-up study].
Lyu JJ; Zhang L; Yan BY; Liu JY; Feng Y; Song LZ; Chen SY; Zhou LB; Liang XF; Cui FQ; Wang FZ; Xu AQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Jun; 50(6):478-83. PubMed ID: 27256725
[TBL] [Abstract][Full Text] [Related]
33. [Antibody persistence following booster vaccination with three doses of hepatitis B vaccines among low-response adults in Zhangqiu county of Shandong province: 24-month of follow-up from 2009].
Yan B; Lyu J; Liu J; Feng Y; Xu A; Chen S; Zhou L; Liang X; Cui F; Wang F; Zhang L
Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Dec; 48(12):1043-7. PubMed ID: 25619213
[TBL] [Abstract][Full Text] [Related]
34. [Antibody persistence following primary vaccination with hepatitis B vaccine among normal and high-responder adults: a 5-year follow-up study].
Wu WL; Yan BY; Lyu JJ; Liu JY; Feng Y; Chen SY; Zhou LB; Liang XF; Cui FQ; Wang FZ; Zhang GM; Zhang L; Xu AQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Jun; 50(6):484-90. PubMed ID: 27256726
[TBL] [Abstract][Full Text] [Related]
35. Improving birth dose coverage of hepatitis B vaccine.
Hipgrave DB; Maynard JE; Biggs BA
Bull World Health Organ; 2006 Jan; 84(1):65-71. PubMed ID: 16501717
[TBL] [Abstract][Full Text] [Related]
36. Safety, immunization coverage and determinants of a new kind of Hepatitis B vaccine firstly applied in Ningbo, China.
Yang S; Ma X; Ni H; Zhou S; Hu D; Shi H; Chen X; Dong H; Xu G
Hum Vaccin Immunother; 2015; 11(12):2819-26. PubMed ID: 26211419
[TBL] [Abstract][Full Text] [Related]
37. Technology update: dissolvable microneedle patches for vaccine delivery.
Rodgers AM; Cordeiro AS; Donnelly RF
Med Devices (Auckl); 2019; 12():379-398. PubMed ID: 31572025
[TBL] [Abstract][Full Text] [Related]
38. Dissolvable microneedle patch containing doxorubicin and docetaxel is effective in 4T1 xenografted breast cancer mouse model.
Bhatnagar S; Bankar NG; Kulkarni MV; Venuganti VVK
Int J Pharm; 2019 Feb; 556():263-275. PubMed ID: 30557681
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis B surface antigen incorporated in dissolvable microneedle array patch is antigenic and thermostable.
Poirier D; Renaud F; Dewar V; Strodiot L; Wauters F; Janimak J; Shimada T; Nomura T; Kabata K; Kuruma K; Kusano T; Sakai M; Nagasaki H; Oyamada T
Biomaterials; 2017 Nov; 145():256-265. PubMed ID: 28915391
[TBL] [Abstract][Full Text] [Related]
40. Ovalbumin-coated pH-sensitive microneedle arrays effectively induce ovalbumin-specific antibody and T-cell responses in mice.
van der Maaden K; Varypataki EM; Romeijn S; Ossendorp F; Jiskoot W; Bouwstra J
Eur J Pharm Biopharm; 2014 Oct; 88(2):310-5. PubMed ID: 24820032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
